Latest Articles

Publication Date
The Microbiota-Endometriosis Axis: An Immune-Endocrine Integration Model and Emerging Therapeutic Targets.

Endometriosis is a chronic, estrogen-dependent inflammatory disorder characterized by the ectopic implantation and persistence of endometrial-like tissue outside the uterine cavity. Despite its high prevalence and significant impact on quality …

Published: May 28, 2026, midnight
Pfizer targets VEGF bispecific white space | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Pfizer targets VEGF bispecific white space | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Published: May 21, 2026, 12:46 p.m.
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Clinical Trials Arena

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial Clinical Trials Arena

Published: May 18, 2026, 4:34 p.m.
Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer - OncLive

Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer OncLive

Published: May 14, 2026, 12:06 a.m.
FGFR2-responsive self-assembled hydrogel releases its inhibitor to suppress the progression of endometriosis.

Fibroblast growth factor receptor 2 (FGFR2) has emerged as a highly promising therapeutic target due to its critical role in the pathogenesis and progression of endometriosis. To date, a variety …

Published: May 9, 2026, midnight
Terazosin as a Non-Hormonal Treatment for Endometriosis.

Endometriosis is a chronic, estrogen-dependent inflammatory disease including aberrant local steroidogenesis, inflammation, angiogenesis, oxidative stress, and prostaglandin-mediated pain. Given the elevated adrenergic receptor expression in endometriotic lesions and the potential …

Published: May 2, 2026, midnight
SGO 2026 – GSK bucks the B7-H4 trend | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

SGO 2026 – GSK bucks the B7-H4 trend | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Published: April 13, 2026, 12:32 p.m.
SGO 2026 – BioNTech’s Enhertu me-too comes up short | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

SGO 2026 – BioNTech’s Enhertu me-too comes up short | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Published: April 13, 2026, 10:30 a.m.
Social Media Health Information Formats and Endometriosis Treatment-Seeking Intentions: A Randomized Controlled Trial.

BackgroundDespite many women learning about endometriosis on social media, posts about the condition often fail to reflect current evidence. With the content and credibility of online health messages being found …

Published: April 13, 2026, midnight
Reply of the authors: Trial emulation and clinical trials.

Published: April 11, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!